Market Research Logo

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2017 in Pharmaceuticals

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceuticals & Healthcare, Global, Deal Summary
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2017
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2017
2.2.1 Novartis to Acquire Advanced Accelerator Applications for USD3.9 Billion
2.2.2 Celgene Prices USD3 Billion in Public Offering of Notes
2.2.3 Eli Lilly and CureVac Enter into Partnership
2.2.4 Amgen and CytomX Therapeutics Enter into Co-Development Agreement
2.2.5 Vir Biotechnology Enters into Licensing Agreement with Visterra
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2017
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2017
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2017
3.1.1 Top M&A Deals in October 2017
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2017 - October 2017
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2017
3.2.1 Top Equity Offering Deals in October 2017
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2017 - October 2017
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2017
3.3.1 Top PE/VC Deals in October 2017
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2017
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2017
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016-October 2017
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-October 2017
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2017
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2017 - October 2017
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2017
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2017
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2017 - October 2017
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2017 - October 2017
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2017
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2017
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2017
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2017 - October 2017
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2017 - October 2017
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2017 - October 2017
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2017 - October 2017
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2017
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2017
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2017
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2017
5.1.1 Oncology - Deals of the Month
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2017
5.2.1 Central Nervous System - Deals of the Month
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2017
5.3.1 Infectious Diseases - Deals of the Month
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2017
5.4.1 Cardiovascular - Deal of the Month
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2017
5.5.1 Immunology - Deals of the Month
5.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, October 2017
5.6.1 Respiratory - Deal of the Month
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, October 2017
5.7.1 Metabolic Disorders - Deal of the Month
6 Deal Summary by Geography
6.1 Pharmaceuticals & Healthcare, North America Deals, October 2017
6.1.1 North America - Deals of the Month
6.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2017
6.2.1 Europe - Deals of the Month
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2017
6.3.1 Asia-Pacific - Deals of the Month
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2017
6.4.1 Rest of the World - Deals of the Month
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2017 - October 2017
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2017 - October 2017
8 Further Information
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclosure information
8.5 Disclaimer
1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2017
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2017
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2017
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2017 - October 2017
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2017
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2017
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2017 - October 2017
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2017
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2017 - October 2017
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2017
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2017 - October 2017
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2017 - October 2017
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2017
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2017 - October 2017
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2017
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2017
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2017
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2017
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2017
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2017
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2017 - October 2017
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2017 - October 2017
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2017
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2017
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2017 - October 2017
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2017 - October 2017
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 - October 2017
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2017 - October 2017
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2017 - October 2017
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2017
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2017 - October 2017
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2017 - October 2017

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2017 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for October 2017 in Pharmaceuticals, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported an increase in the number of deals and deal values in October 2017. The industry reported 432 deals worth USD31.3 billion in October 2017, compared to 395 deals worth USD28.2 billion in September 2017. The oncology therapeutics market remained at the top in deal activity in October 2017 with 157 deals. In second place, infectious disease therapeutics market reported 92 deals. Licensing agreements in pharmaceutical and healthcare industry registered a decrease in upfront payments. The segment reported USD57.4m as upfront payments in October 2017, compared to USD87.5m in September 2017. The number of deals in North America an increased to 286 in October 2017 from 245 in September 2017.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;